With similar PK parameters and probabilities of DLTs between the QD and BID dosing regimens [16, 30, 31, 47], the 40-mg BID dose has been widely approved and the 80-mg QD dose has been approved in some countries for patients with CML-CP after ≥ 2 TKIs without BCR::ABL1T315I [26, 27, 31]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.